Zachrisson, O, Colque-Navarro, P, Gottfries, C G et al. · European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2004 · DOI
Researchers tested whether a vaccine made from killed bacteria could help people with ME/CFS and fibromyalgia by stimulating their immune system. Half of 28 patients received the vaccine and half received placebo over 6 months. Patients who received the vaccine developed antibodies (immune proteins) against bacterial toxins, and those with stronger antibody responses showed more clinical improvement.
This study offers early evidence that ME/CFS patients may benefit from immune-directed therapies that generate specific antibody responses, and demonstrates a potential biomarker (antibody levels) that could be used to predict treatment response. Understanding immune mechanisms in ME/CFS remains a priority for developing targeted interventions.
This study does not prove that bacterial toxins cause ME/CFS or that vaccination is a safe or effective standard treatment. The correlation between antibody response and clinical improvement does not establish causation—both could result from a third factor. The small sample size and exploratory nature mean results require replication in larger, well-controlled trials before clinical recommendations can be made.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →